Protein phosphatase PP5 controls bone mass and the negative effects of rosiglitazone on bone through reciprocal regulation of PPAR? (peroxisome proliferator-activated receptor ?) and RUNX2 (runt-related transcription factor 2)
Type
Retraction
Notice date
5/25/2018 0:00
Journal
The Journal of Biological Chemistry
Publisher
American Society for Biochemistry and Molecular Biology (ASBMB)